Tumor HGF lacks prognostic significance in Mexican breast cancer patients

Journal of Experimental and Clinical Cancer Research

Volumn 25, Issue 3, 2006, Pages 357-364

  Pruefer, F G ^a   Unger Saldana K ^a   Mohamier, L ^a   Ramirez M ^a   Suarez J ^a   Ramirez, M T ^a   Maldonado, Vilma ^a   Meléndez Zajgla, Jorge ^a  

^a INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

Author keywords

Breast cancer; Hepatocyte growth factor, HGF, Scatter factor, SF, Survival, Prognosis

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; SCATTER FACTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER SURVIVAL; CONTROLLED STUDY; CORRELATIONAL STUDY; ENZYME IMMUNOASSAY; FEMALE; HUMAN; HUMAN TISSUE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MEXICO; PRIORITY JOURNAL; PROGNOSIS; SURGICAL TECHNIQUE; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOENZYME TECHNIQUES; MEXICO; MIDDLE AGED; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 33751092528     PISSN: 03929078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Breast cancer statistics. J. Natl. Cancer. Inst. 92: 445, 2000.
2. Rodriguez-Cuevas S., Macias C. G., Franceschi D. and Labastida S.: Breast carcinoma presents a decade earlier in Mexican women than in women in the United States or European countries. Cancer. 91: 863-868, 2001.
3. Registro Histopatológico de Neoplasias Malignas. México. Mexico City Secretaria de Salud. Dirección General de Epidemiología, 2001.
4. Clinical and Biostatistics Archive of the Mexican National Cancer Institute. 1980-2005.
5. Nakamura T., Teramoto H. and Ichihara A.: Purification and characterization of a growth factor from rat platelets for mature parenchymal hepatocytes in primary cultures. Proc. Natl. Acad. Sci. USA. 83: 6489-6493, 1986.
6. Jiang W. G. and Hiscox S.: Hepatocyte growth factor/scatter factor, a cytokine playing multiple and converse roles. Histol. Histopathol. 12: 537-555, 1997.
7. Bottaro D. P., Rubin J. S., Faletto D. L., Chan A. M., Kmiecik T. E., Vande Woude G. F. and Aaronson S. A.: Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 251: 802-804, 1991.
8. Rong S., Segal S., Anver M., Resau J. H. and Vande Woude G. F.: Invasiveness and metastasis of NIH 3T3 cells induced by Met-hepatocyte growth factor/scatter factor autocrine stimulation. Proc. Natl. Acad. Sci. USA 91: 4731-4735, 1994.
9. Gallego M. I., Bierie B. and Hennighausen L.: Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene. 22: 8498-8508, 2003.
10. Abounader R., Lal B., Luddy C., Koe G., Davidson B., Rosen E. M. and Laterra J.: In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. Faseb. J. 16: 108-110, 2002.
11. Herynk M. H., Stoeltzing O., Reinmuth N., Parikh N. U., Abounader R., Laterra J., Radinsky R., Ellis L. M. and Gallick G. E.: Down-regulation of c-Met inhibits growth in the liver of human colorectal carcinoma cells. Cancer Res. 63: 2990-2996, 2003.
12. Jiang W. G., Grimshaw D., Lane J., Martin T. A., Abounader R., Laterra J. and Mansel R. E.: A hammerhead ribozyme suppresses expression of hepatocyte growth factor/scatter factor receptor c-MET and reduces migration and invasiveness of breast cancer cells. Clin. Cancer Res. 7: 2555-2562, 2001.
13. Hiscox S., Parr C., Nakamura T., Matsumoto K., Mansel R. E. and Jiang W. G.: Inhibition of HGF/SF-induced breast cancer cell motility and invasion by the HGF/SF variant, NK4. Breast Cancer Res. Treat. 59: 245-254, 2000.
14. Jiang W. G., Grimshaw D., Martin T. A., Davies G., Parr C., Watkins G., Lane J., Abounader R., Laterra J. and Mansel R. E.: Reduction of stromal fibroblast-induced mammary tumor growth, by retroviral ribozyme transgenes to hepatocyte growth factor/scatter factor and its receptor, c-MET. Clin. Cancer Res. 9: 4274-4281, 2003.
15. Martin T. A., Parr C., Davies G., Watkins G., Lane J., Matsumoto K., Nakamura T., Mansel R. E. and Jiang W. G.: Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, a HGF/SF antagonist. Carcinogenesis. 24: 1317-1323, 2003.
16. Yamashita J., Ogawa M. and Beppu T.: Immunoreactive hepatocyte growth factor is present in tissue extracts from human breast cancer but not in conditioned medium of human breast cancer cell lines. Res. Commun. Chem. Pathol. Pharmacol. 82: 249-252, 1993.
17. Wang Y., Selden A. C., Morgan N., Stamp G. W. and Hodgson H. J.: Hepatocyte growth factor/scatter factor expression in human mammary epithelium. Am. J. Pathol. 144: 675-682, 1994.
18. Fukuda T., Ichimura E., Shinozaki T., Sano T., Kashiwabara K., Oyama T., Nakajima T. and Nakamura T.: Coexpression of HGF and c-Met/HGF receptor in human bone and soft tissue tumors. Pathol. Int. 48: 757-762, 1998.
19. Borset M., Seidel C., Hjorth-Hansen H., Waage A. and Sundan A.: The role of hepatocyte growth factor and its receptor c-Met in multiple myeloma and other blood malignancies. Leuk. Lymphoma. 32: 249-256, 1999.
20. Yamashita J., Ogawa M., Yamashita S., Nomura K., Kuramoto M., Saishoji T. and Shin S.: Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer. Cancer Res. 54: 1630-1633, 1994.
21. Taniguchi T., Toi M., Inada K., Imazawa T., Yamamoto Y. and Tominaga T.: Serum concentrations of hepatocyte growth factor in breast cancer patients. Clin. Cancer. Res. 1: 1031-1034, 1995.
22. Jin L., Fuchs A., Schnitt S. J., Yao Y., Joseph A., Lamszus K., Park M., Goldberg I. D. and Rosen E. M.: Expression of scatter factor and c-met receptor in benign and malignant breast tissue. Cancer. 79: 749-760, 1997.
23. Yao Y., Jin L., Fuchs A., Joseph A., Hastings H. M., Goldberg I. D. and Rosen E. M.: Scatter factor protein levels in human breast cancers: clinicopathological and biological correlations. Am. J. Pathol. 149: 1707-1717, 1996.
24. Nagy J., Curry G. W., Hillan K. J., McKay I. C., Mallon E., Purushotham A. D. and George W. D.: Hepatocyte growth factor/scatter factor expression and c-met in primary breast cancer. Surg. Oncol. 5: 15-21, 1996.
25. Maemura M., Iino Y., Yokoe T., Horiguchi J., Takei H., Koibuchi Y., Horii Y., Takeyoshi I., Ohwada S. and Morishita Y.: Serum concentration of hepatocyte growth factor in patients with metastatic breast cancer. Cancer Lett. 126: 215-220, 1998.
26. Toi M., Taniguchi T., Ueno T., Asano M., Funata N., Sekiguchi K., Iwanari H. and Tominaga T.: Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer. Clin. Cancer Res. 4: 659-664, 1998.
27. Kang J. Y., Dolled-Filhart M., Ocal I. T., Singh B., Lin C. Y., Dickson R. B., Rimm D. L. and Camp R. L.: Tissue microarray analysis of hepatocyte growth factor/Met pathway components reveals a role for Met, matriptase, and hepatocyte growth factor activator inhibitor 1 in the progression of node-negative breast cancer. Cancer Res. 63: 1101-1105, 2003.
28. Parr C., Watkins G., Mansel R. E. and Jiang W. G.: The hepatocyte growth factor regulatory factors in human breast cancer. Clin. Cancer Res. 10: 202-211, 2004.
29. Elledge R. M., Clark G. M., Chamness G. C. and Osborne C. K.: Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J. Natl. Cancer Inst. 86: 705-712, 1994.
30. Newman L. A., Mason J., Cote D., Vin Y., Carolin K., Bouwman D. and Colditz G. A.: African-American ethnicity, socioeconomic status, and breast cancer survival: a meta-analysis of 14 studies involving over 10,000 African-American and 40,000 White American patients with carcinoma of the breast. Cancer. 94: 2844-2854, 2002.
31. Porter P. L., Lund M. J., Lin M. G., Yuan X., Liff J. M., Flagg E. W., Coates R. J. and Eley J. W.: Racial differences in the expression of cell cycle-regulatory proteins in breast carcinoma. Cancer. 100: 2533-2542, 2004.
32. Ademuyiwa F. O. and Olopade O. I.: Racial differences in genetic factors associated with breast cancer. Cancer Metastasis Rev. 22: 47-53, 2003.
33. Stark A. T., Claud S., Kapke A., Lu M., Linden M. and Griggs J.: Race modifies the association between breast carcinoma pathologic prognostic indicators and the positive status for HER-2/neu. Cancer. 104: 2189-2196, 2005.
34. Pande S. V. and Murthy M. S.: A modified micro-Bradford procedure for elimination of interference from sodium dodecyl sulfate, other detergents, and lipids. Anal. Biochem. 220: 424-426, 1994.
35. Jeffers M., Rao M. S., Rulong S., Reddy J. K., Subbarao V., Hudson E., Vande Woude G. F. and Resau J. H.: Hepatocyte growth factor/scatter factor-Met signaling induces proliferation, migration, and morphogenesis of pancreatic oval cells. Cell Growth Differ. 7: 1805-1813, 1996.
36. Uchida D., Kawamata H., Omotehara F., Nakashiro K., Kimura-Yanagawa T., Hino S., Begum N. M., Hoque M. O., Yoshida H., Sato M. and Fujimori T.: Role of HGF/c-met system in invasion and metastasis of oral squamous cell carcinoma cells in vitro and its clinical significance. Int. J. Cancer. 93: 489-496, 2001.
37. Trusolino L., Cavassa S., Angelini P., Ando M., Bertotti A., Comoglio P. M. and Boccaccio C.: HGF/scatter factor selectively promotes cell invasion by increasing integrin avidity. Faseb. J. 14: 1629-1640, 2000.
38. Harvey P., Warn A., Dobbin S., Arakaki N., Daikuhara Y., Jaurand M. C. and Warn R. M.: Expression of HGF/SF in mesothelioma cell lines and its effects on cell motility, proliferation and morphology. Br. J. Cancer. 77: 1052-1059, 1998.
39. Moriyama T., Kataoka H., Seguchi K., Tsubouchi H. and Koono M.: Effects of hepatocyte growth factor (HGF) on human glioma cells in vitro: HGF acts as a motility factor in glioma cells. Int. J. Cancer. 66: 678-685, 1996.
40. Rosen E. M., Grant D. S., Kleinman H. K., Goldberg I. D., Bhargava M. M., Nickoloff B. J., Kinsella J. L. and Polverini P.: Scatter factor (hepatocyte growth factor) is a potent angiogenesis factor in vivo. Symp. Soc. Exp. Biol. 47: 227-234, 1993.
41. Bardelli A., Longati P., Albero D., Goruppi S., Schneider C., Ponzetto C. and Comoglio P. M.: HGF receptor associates with the anti-apoptotic protein BAG-1 and prevents cell death. Embo J. 15: 6205-6212, 1996.
42. Gao M., Fan S., Goldberg I. D., Laterra J., Kitsis R. N. and Rosen E. M.: Hepatocyte growth factor/scatter factor blocks the mitochondrial pathway of apoptosis signaling in breast cancer cells. J. Biol. Chem. 276: 47257-47265, 2001.
43. Fan S., Ma Y. X., Wang J. A., Yuan R. Q., Meng Q., Cao Y., Laterra J. J., Goldberg I. D. and Rosen E. M.: The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3′ kinase. Oncogene. 19: 2212-2223, 2000.
44. Pasdar M., Li Z., Marreli M., Nguyen B. T., Park M. and Wong K.: Inhibition of junction assembly in cultured epithelial cells by hepatocyte growth factor/scatter factor is concomitant with increased stability and altered phosphorylation of the soluble junctional molecules. Cell. Growth. Differ. 8: 451-462, 1997.
45. Martin T. A., Watkins G., Mansel R. E. and Jiang W. G.: Hepatocyte growth factor disrupts tight junctions in human breast cancer cells. Cell. Biol. Int. 28: 361-371, 2004.
46. Tajima H., Matsumoto K. and Nakamura T.: Hepatocyte growth factor has potent anti-proliferative activity in various tumor cell lines. FEBS Lett. 291: 229-232, 1991.
47. Shiota G., Rhoads D. B., Wang T. C., Nakamura T. and Schmidt E. V.: Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. Proc. Natl. Acad. Sci. USA. 89: 373-377, 1992.
48. Tsukada Y., Tanaka T., Miyazawa K. and Kitamura N.: Involvement of down-regulation of Cdk2 activity in hepatocyte growth factor-induced cell cycle arrest at G1 in the human hepatocellular carcinoma cell line HepG2. J. Biochem. (Tokyo). 136: 701-709, 2004.
49. Conner E. A., Wirth P. J., Kiss A., Santoni-Rugiu E. and Thorgeirsson S. S.: Growth inhibition and induction of apoptosis by HGF in transformed rat liver epithelial cells. Biochem. Biophys. Res. Commun. 236: 396-401, 1997.
50. Arakaki N., Kazi J. A., Kazihara T., Ohnishi T. and Daikuhara Y.: Hepatocyte growth factor/scatter factor activates the apoptosis signaling pathway by increasing caspase-3 activity in sarcoma 180 cells. Biochem. Biophys. Res. Commun. 245: 211-215, 1998.
51. ler. Consenso Nacional sobre Diagnóstico y Tratamiento del Cáncer Mamario. Cir. Gral. 19: 227-234, 1997.